These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9922319)

  • 1. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.
    Sobesky R; Mathurin P; Charlotte F; Moussalli J; Olivi M; Vidaud M; Ratziu V; Opolon P; Poynard T
    Gastroenterology; 1999 Feb; 116(2):378-86. PubMed ID: 9922319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
    Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
    Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
    Poynard T; Bedossa P; Opolon P
    Lancet; 1997 Mar; 349(9055):825-32. PubMed ID: 9121257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.
    Poynard T; McHutchison J; Davis GL; Esteban-Mur R; Goodman Z; Bedossa P; Albrecht J
    Hepatology; 2000 Nov; 32(5):1131-7. PubMed ID: 11050066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time?
    Guido M; Bortolotti F; Leandro G; Jara P; Hierro L; Larrauri J; Barbera C; Giacchino R; Zancan L; Balli F; Crivellaro C; Cristina E; Pucci A; Rugge M
    Am J Gastroenterol; 2003 Mar; 98(3):660-3. PubMed ID: 12650803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B.
    Papatheodoridis GV; Petraki K; Cholongitas E; Kanta E; Ketikoglou I; Manesis EK
    J Viral Hepat; 2005 Mar; 12(2):199-206. PubMed ID: 15720536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
    Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis.
    Ingiliz P; Valantin MA; Preziosi P; Finzi L; Pais R; Fedchuk L; Dominguez S; Katlama C; Poynard T; Benhamou Y
    J Hepatol; 2012 Jan; 56(1):49-54. PubMed ID: 21781946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
    Zarski JP; Sturm N; Desmorat H; Melin P; Raabe JJ; Bonny C; Sogni P; Pinta A; Rouanet S; Babany G; Cheveau A; Chevallier M
    Liver Int; 2010 Aug; 30(7):1049-58. PubMed ID: 20492512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection.
    Chen Yi Mei SLG; Thompson AJ; Christensen B; Cunningham G; McDonald L; Bell S; Iser D; Nguyen T; Desmond PV
    PLoS One; 2017; 12(10):e0185609. PubMed ID: 29065124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible role of angiotensin-converting enzyme polymorphism on progression of hepatic fibrosis in chronic hepatitis C virus infection.
    Raslan HM; Amr KS; Elhosary YA; Ezzat WM; Abdullah NA; El-Batae HE
    Trans R Soc Trop Med Hyg; 2011 Jul; 105(7):396-400. PubMed ID: 21546048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.
    Shiratori Y; Imazeki F; Moriyama M; Yano M; Arakawa Y; Yokosuka O; Kuroki T; Nishiguchi S; Sata M; Yamada G; Fujiyama S; Yoshida H; Omata M
    Ann Intern Med; 2000 Apr; 132(7):517-24. PubMed ID: 10744587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-interventional phase IV Belgian survey to assess the antiviral effectiveness of pegylated interferon-alpha-2b and ribavirin treatment according to the stage of liver fibrosis in previously untreated patients with genotype 1/4/5/6 chronic hepatitis C (PRACTICE).
    Bourgeois S; Deltenre P; Delwaide J; Henrion J; Adler M; Langlet P; Mulkay JP; Nevens F; Brixko C; Moreno C
    Acta Gastroenterol Belg; 2014 Dec; 77(4):393-400. PubMed ID: 25682628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.
    Heathcote EJ; Shiffman ML; Cooksley WG; Dusheiko GM; Lee SS; Balart L; Reindollar R; Reddy RK; Wright TL; Lin A; Hoffman J; De Pamphilis J
    N Engl J Med; 2000 Dec; 343(23):1673-80. PubMed ID: 11106716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.